Condition

HER2-Negative Breast Carcinoma clinical trials and research

• 16Clinical trials
• 24Countries

Newest HER2-Negative Breast Carcinoma clinical trials

All recruiting trials (16)

• Pre-surgery hormone therapy to lower positive margins in lobular breast cancer

  This Phase 2 trial tests whether giving endocrine (hormone) therapy before breast-conserving surgery can reduce the chance of cancer at the edges of the removed tissue in postmenopausal people with ER+/HER2- invasive lobular breast cancer.

  Recruiting at 7 sites Phase 2 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT07483307

• Hormone therapy with ribociclib vs chemotherapy followed by hormone therapy with ribociclib for high-risk stage breast cancer

  This trial tests whether hormone therapy with ribociclib works as well as chemotherapy followed by hormone therapy with ribociclib for patients with high-stage, estrogen receptor-positive, HER2-negative breast cancer at low risk of recurrence.

  Recruiting at 257 sites Phase 3 National Cancer Institute (NCI) · Jonesboro, Arkansas and 257 other locations · NCT07391774

• Preoperative chemotherapy with pembrolizumab and a low or high radiation boost for node-positive triple-negative breast cancer

  This study tests whether giving a low or high radiation boost together with preoperative chemotherapy and pembrolizumab can better activate the immune system in people with node‑positive triple‑negative breast cancer.

  Recruiting Phase 2 UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07276880

• Palazestrant plus ribociclib as first-line treatment for ER+/HER2- advanced breast cancer

  This trial will test whether using palazestrant instead of letrozole, both given with ribociclib, helps adults with ER+/HER2- advanced breast cancer who have not had prior systemic treatment for their advanced disease.

  Recruiting at 198 sites Phase 3 Olema Pharmaceuticals, Inc. · Hot Springs, Arkansas and 199 other locations · NCT07085767

• Antibody-drug conjugates for first- and second-line treatment of metastatic HER2‑negative and triple‑negative breast cancer

  This prospective registry will collect real-world data to see how FDA-approved antibody-drug conjugates work as first- or second-line treatments for adults with metastatic HER2‑negative or triple-negative breast cancer.

  Recruiting at 3 sites University of California, San Francisco · San Francisco, California and 2 other locations · NCT06774027

• Testing Abemaciclib with Radiation Therapy for Metastatic Breast Cancer

  This study is testing different doses of the drug abemaciclib in people with metastatic breast cancer who are also getting hormone therapy and radiation to see if it helps them better manage their symptoms.

  Recruiting at 7 sites Phase 1 Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT06678269

• Using acupuncture and acupressure to reduce joint pain in Black women with early-stage breast cancer

  This study is testing whether acupuncture and virtual acupressure can help reduce joint pain for Black women with early-stage breast cancer who are taking hormone therapy.

  Recruiting at 4 sites Emory University · Atlanta, Georgia and 3 other locations · NCT06534125

• Using turkey tail mushroom to treat post-menopausal women with specific breast cancer before surgery

  This study is testing if taking turkey tail mushroom can help post-menopausal women with a specific type of breast cancer feel better and improve their tumors before surgery.

  Recruiting Phase 2 Mayo Clinic · Scottsdale, Arizona · NCT06450873

• Measuring a biomarker for breast cancer treatment effectiveness

  This study is testing if measuring a specific biomarker can help doctors understand how well hormone treatments are working for people with advanced breast cancer.

  Recruiting Mayo Clinic · Jacksonville, Florida · NCT06388122

• Datopotamab deruxtecan for treating breast cancer that has spread to the brain

  This study is testing a new drug called datopotamab deruxtecan to see if it can help people with HER2-negative breast cancer that has spread to the brain.

  Recruiting at 3 sites Phase 2 Dana-Farber Cancer Institute · Miami, Florida and 2 other locations · NCT06176261

• Combining an immunotherapy drug with standard chemotherapy for advanced breast cancer

  This study is testing if adding an immunotherapy drug called durvalumab to standard chemotherapy can help people with advanced hormone receptor-positive, HER2-negative breast cancer live longer and feel better.

  Recruiting at 552 sites Phase 3 National Cancer Institute (NCI) · Birmingham, Alabama and 564 other locations · NCT06058377

• Dose-reduced chemotherapy for older women with early-stage HER2 negative breast cancer

  This study is testing if a lower dose of chemotherapy can help older women with early-stage HER2 negative breast cancer feel better during treatment compared to the standard dose.

  Recruiting at 3 sites Phase 2 City of Hope Medical Center · Duarte, California and 2 other locations · NCT06042569

• Gemcitabine and NK cells with or without Naxitamab for metastatic HER2-negative breast cancer

  This study is testing a new treatment using gemcitabine and special immune cells, with or without naxitamab, to see if it helps people with advanced HER2-negative breast cancer feel better and live longer.

  Recruiting Phase 1/2 Ohio State University Comprehensive Cancer Center · Columbus, Ohio · NCT06026657

• Biobehavioral stress reduction for patients with triple negative breast cancer

  This study is testing a stress reduction program for people who have just been diagnosed with triple negative breast cancer to see if it helps them feel better and cope with their situation.

  Recruiting at 2 sites Ohio State University Comprehensive Cancer Center · Cleveland, Ohio and 1 other locations · NCT05677802

• Combining letrozole and simvastatin to treat hormone receptor positive breast cancer

  This study tests if combining letrozole with simvastatin can help shrink tumors in postmenopausal women with hormone receptor positive breast cancer better than using letrozole alone.

  Recruiting at 4 sites Early Phase 1 Emory University · Atlanta, Georgia and 3 other locations · NCT05464810

• Treatment for metastatic cancer with BRCA or PALB2 mutations using chemotherapy and stem cells

  This study is testing a new treatment combining chemotherapy and stem cells for people with metastatic pancreatic or breast cancer who have BRCA or PALB2 mutations to see if it is safe and effective.

  Recruiting Phase 1 General Oncology, Inc. · Boston, Massachusetts and 1 other locations · NCT04150042

Related topics

Quick answers

How many HER2-Negative Breast Carcinoma clinical trials are recruiting right now?

16, as of November 12, 2026. We update this list each time we refresh our data from ClinicalTrials.gov.

Where are these trials running?

In 24 countries. The most sites are in United States (16 trials), Puerto Rico (2 trials), Australia (1 trial), Austria (1 trial), Belgium (1 trial). Each study page lists its sites and which ones are recruiting.

What phases are they in?

Phase 2: 5, Phase 3: 3, Phase 1: 2, Early Phase 1: 1. Trials with no phase listed are usually device, behavioural or observational studies.

How do I join one?

Open a study, check the "Is this trial a fit for you?" section, then contact the study team listed on the page. They will ask a few screening questions. Asking is free and does not commit you to anything. Talk it over with your doctor first.

Find the studies that fit you

A list is a starting point. Tell us your situation in your own words and we'll rank the studies that match and explain why. It's free and needs no account.

Describe your situation →